Genetic interaction between GROWTH-REGULATING FACTOR and CUP-SHAPED COTYLEDON in organ separation.

The Arabidopsis thaliana GROWTH-REGULATING FACTOR (GRF) gene family comprises 9 members and encodes a class of transcription factors. We previously demonstrated that GRF genes played an essential role in formation of the boundary region between cotyledons, since their loss-of-function mutants developed fused cotyledons. Our present study shows that the grf mutants display fused floral organs as well. Such fusion phenotypes of embryonic and post-embryonic floral organs are highly reminiscent of the cup-shaped cotyledon (cuc) mutants. In order to test a genetic interaction between GRFs and CUCs, we constructed cuc1 grf1/2/3, cuc2 grf1/2/3, and cuc3 grf1/2/3 quadruple mutants, and found that the mutants showed dramatic increases in cotyledon fusion as well as floral organ fusion. The results suggest that the signaling pathway of GRFs may be genetically associated with that of CUCs in the organ separation process.

Designed nanocage displaying ligand-specific Peptide bunches for high affinity and biological activity.

Protein-cage nanoparticles are promising multifunctional platforms for targeted delivery of imaging and therapeutic agents owing to their biocompatibility, biodegradability, and low toxicity. The major advantage of protein-cage nanoparticles is the ability to decorate their surfaces with multiple functionalities through genetic and chemical modification to achieve desired properties for therapeutic and/or diagnostic purposes. Specific peptides identified by phage display can be genetically fused onto the surface of cage proteins to promote the association of nanoparticles with a particular cell type or tissue. Upon symmetrical assembly of the cage, peptides are clustered on the surface of the cage protein in bunches. The resulting PBNC (peptide bunches on nanocage) offers the potential of synergistically increasing the avidity of the peptide ligands, thereby enhancing their blocking ability for therapeutic purposes. Here, we demonstrated a proof-of-principle of PBNCs, fusing the interleukin-4 receptor (IL-4R)-targeting peptide, AP-1, identified previously by phage display, with ferritin-L-chain (FTL), which undergoes 24-subunit assembly to form highly stable AP-1-containing nanocage proteins (AP1-PBNCs). AP1-PBNCs bound specifically to the IL-4R-expressing cell line, A549, and their binding and internalization were specifically blocked by anti-IL-4R antibody. AP1-PBNCs exhibited dramatically enhanced binding avidity to IL-4R compared with AP-1 peptide, measured by surface plasmon resonance spectroscopy. Furthermore, treatment with AP1-PBNCs in a murine model of experimental asthma diminished airway hyper-responsiveness and eosinophilic airway inflammation along with decreased mucus hyperproduction. These findings hold great promise for the application of various PBNCs with ligand-specific peptides in therapeutics for different diseases, such as cancer.